MET Mutation Analysis detects the somatic splice site mutations at exon 14 of the MET gene from formalin-fixed paraffin-embedded tissues (FFPE). MET exon 14 alterations were shown to promote RNA-splicing–based skipping of MET exon 14, which results in activation of MET kinase activity. MET exon 14 alterations have been shown to occur in approximately 3% of lung adenocarcinoma cases and have also been observed in neuroblastoma and gastric cancer cell lines1. Targeted therapies inhibiting MET signaling would be beneficial for patients with MET exon14 alterations.
- Framton et al. “Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug;5(8):850-9